Abstract library

1011 results for "treatment guidelines".
#1590 Treatment of Metastatic Pancreatic Neuroendocrine Tumors: Relevance of ENETS 2016 Guidelines
Introduction: The choice of first-line treatment of metastatic pancreatic neuroendocrine tumors (mP-NET) is mainly based on prognostic factors. ENETS-2016 guidelines proposed treatments according to 3 groups: Group-1, patients in whom all lesions could be removed; Group-2, patients with Ki67<10%, low tumor burden, no symptoms, and stable disease, for whom a watch-and-wait strategy or somatostatin analogs are proposed; Group-3, symptomatic patients or with Ki67>10% or significant tumor burden or progressive disease, for whom a systemic chemotherapy is proposed
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Margaux Foulfoin
Authors:
Keywords: pancreas, metastasis
#2052 Oral Carcinoid Mimicking as non Healing Ulcer. A Case Report.
Introduction: Neuroendocrine tumors are the aggressive tumors resulting in sheer morbidity and mortality of the patients. The true origin of oral neuroendocrine carcinomas remains unclear.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Dr Arooj Fatima
Authors:
#1896 Launching NETwerk: Diagnosis and Treatment of Neuroendocrine Tumors within a Multi-Institutional Collaboration in the Region of Antwerp-Waasland in Belgium
Introduction: Centralizing cancer services is one way to improve global outcome for cancer patients but brings along that patients must be motivated to travel and that doctors of local hospitals get deprived of the diagnostic and treatment skills. The alternative way is to centrally coordinate cancer services across different hospitals. In this scenario, local multidisciplinary teams refer all patients to be discussed among cancer specialists. This continuous feed-back system also creates the opportunity to propose additional more specific and sensitive examinations for individual patients which would introduce the end of local substandard treatment.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Prof. Marc Peeters
Authors:
#128 Multidisciplinary reference centers: the need for combined expertise in the diagnosis and treatment of neuroendocrine tumors
Introduction: Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies with increasing incidence (Yao et al. J Clin Oncol 2008;26:3063–72). Multidisciplinary reference centers (MRCs) can potentially offer better clinical outcomes by integrating and coordinating expert care from many specialties, reducing delays in treatments and referrals, and allowing for accrual to clinical trials. MRCs have achieved improved outcomes in ovarian, breast and lung cancers (Pollock. Ann Surg 2008;248:510–6; Gabel et al. Cancer 1997;79:2380–4; Forrest et al. Br J Cancer 2005;93:977–8). Despite this, MRCs focusing on NETs are uncommon.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Simron Singh
Authors:
#1785 Eterogeneity of Duodenal Neuroendocrine Tumors: A Multi-Centre Experience in Italy
Introduction: Duodenal neuroendocrine neoplasms (dNENs) are heterogeneous tumors, which could have a highly variable prognosis.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: dr Sara Massironi
Authors:
#2138 Eterogeneity of Duodenal Neuroendocrine Tumors: A Multi-Centre Experience In Italy
Introduction: The optimal management of duodenal neuroendocrine neoplasms (dNENs) is unclear and endoscopic resection is increasingly performed instead of surgery.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MD Roberta Elisa Rossi
Authors:
#2194 Therapeutic Sequences in Patients with G1-G2 Neuroendocrine Tumors (NETs): An Observational, Multicentre, Prospective/Retrospective Study
Introduction: Many different therapies are suggested by guidelines to treat loco-regionally advanced or metastatic G1-G2 neuroendocrine tumors (NETs). However, a precise therapeutic algorithm has not yet been established.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD, PhD Antongiulio Faggiano
Authors:
#652 Neuroendocrine Neoplasms in Childhood and Adolescents
Introduction: NEN are very rare tumors in children and adolescents with predominance in adolescent girls. The annual incidence is about 1.14:1 million. The most frequent localization is appendix. Bronchial NEN, even extremly rare, is the most frequent primary epithelial lung tumor in children.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD,PhD Viera - Bajciova
Authors:
#83 Surgical treatment of duodenopancreatic neuroendocrine tumors (pNETs) in patients with multiple endocrine neoplasia type 1 (MEN 1): a Dutch consensus statement
Introduction: Duodenopancreatic neuroendocrine tumors (pNETs) in multiple endocrine neoplasia type 1 (MEN 1) are the most important cause of MEN 1-related death. Surgery is the only curative treatment, but controversy exists on the optimal strategy. Recent guidelines on pNETs have limited recommendations specific for MEN 1. Therefore, a Dutch multidisciplinary consensus meeting was organized.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Carolina RC Pieterman
Authors:
#1456 Retreatment with Peptide-Receptor Radionuclide Therapy: Effects on Long-term Survival, Renal and Bone Marrow Toxicity Using Yttrium-90 vs. Lutetium-177
Introduction: PRRT is an effective treatment for metastatic NETs. The effect of PRRT retreatment is unknown.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Joseph Machta
Authors:
Keywords: PRRT, retreatment